Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)
NCT01931306
·
clinicaltrials.gov ↗
APPROVED_FOR_MARKETING
Status
INDUSTRY
Sponsor class
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG:
Afatinib
Sponsor
Boehringer Ingelheim